It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Despite insufficient data, writing panel will give recommendations for preparation, transfer, and follow-up for youth with ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the “frenzy” of weight loss drugs.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Ahead of a Senate health committee hearing next week with Novo Nordisk CEO Lars Jørgensen, Sen. Bernie Sanders claims he has ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

Rhythm Pharmaceuticals (RYTM) stock gains as JMP Securities issues a positive view on the company citing its lead product ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...